Evidence map›Paper›PMID 38902531›Full record

ArticleBritish journal of cancer2024

Anti-PEc: Development of a novel monoclonal antibody against prostate cancer.

Athanasios Armakolas, Nektarios Alevizopoulos, Martha Stathaki, Constantina Petraki, George Agrogiannis, Martina Samiotaki, George Panayotou, Eirini Chatzinikita, Michael Koutsilieris

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in British journal of cancer, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Athanasios ArmakolasPhysiology Laboratory, Medical School, National and Kapodestrian University of Athens, Athens, Greece. aarmakol@med.uoa.gr.ORCID http://orcid.org/0000-0002-5864-1818
Nektarios Alevizopoulos *Physiology Laboratory, Medical School, National and Kapodestrian University of Athens, Athens, Greece.
Martha Stathaki *Surgical Department, Elena Venizelou Hospital, Athens, Greece.
Constantina PetrakiDepartment of Pathology, Metropolitan General Hospital, Athens, Greece.
George AgrogiannisDepartment of Pathology, University of Athens, Medical School, National and Kapodestrian University of Athens, Athens, Greece.
Martina SamiotakiBioinnovation Institute, Biomedical Science Research Center "Alexander Fleming.", Vari, Greece.
George PanayotouBioinnovation Institute, Biomedical Science Research Center "Alexander Fleming.", Vari, Greece.
Eirini ChatzinikitaPhysiology Laboratory, Medical School, National and Kapodestrian University of Athens, Athens, Greece.
Michael KoutsilierisPhysiology Laboratory, Medical School, National and Kapodestrian University of Athens, Athens, Greece.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe Ec peptide (PEc) that defines the IGF-1Ec isoform, is associated with prostate cancer progression by inducing proliferation, metastases, and tumour repair. On these grounds, an anti-PEc monoclonal antibody (MAb) was developed. Our objective is to examine the effects of this antibody on prostate cancer and its possible side effects.

methodsThe effects of the obtained MAb were examined in cancer and non-cancerous cell lines (unmodified and modified either to overexpress or silence PEc) and in tumours in SCID mice injected with unmodified prostate cancer cells. The investigation was obtained with respect to cellular proliferation, migration, invasion, toxicity to tumours, effects on the cell cycle, immune response activation, effects on mesenchymal stem cell mobilisation leading to tumour repair, tissue distribution, and toxicity to mice.

resultsAnti-PEc MAb treatment led to a significant decrease in cellular proliferation, migration, and invasion compared to the untreated cell lines (p < 0.0005 in every case). Mechanistically, these effects were associated with the downregulation of pERK1/2 and vimentin and the upregulation of E-Cadherin. In vivo, anti-PEc MAb treatment was associated with a significant decrease in tumour size and metastases rate (p < 0.0005 in every case) by reversing the tumours mesenchymal phenotype. It also inhibited host stem cell mobilisation towards the tumour, leading to apoptosis. Anti-PEc MAb assessment in respect to distribution and toxicity, indicated its tumour specificity and lack of toxicity.

conclusionsThese data indicate that the therapeutic targeting of PEc with the anti-PEc MAb may have considerable clinical benefit for prostate cancer patients.

Indexed as

Antibodies, MonoclonalCell ProliferationMice, SCIDProstatic NeoplasmsAnimalsCell Line, TumorCell MovementHumansInsulin-Like Growth Factor IMaleMiceXenograft Model Antitumor AssaysAntibodies, MonoclonalInsulin-Like Growth Factor I

Identifiers

PMID38902531
PMCPMC11300853

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.